Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRROR: Cetuximab-IRDye800CW and 5-ALA for Fluorescence Guided Surgery in High-grade Glioma
NCT05929456Phase 1Unknown
- Sponsor
- University Medical Center Groningen
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW in glioma, sponsored by University Medical Center Groningen. Primary endpoints: Optimal dosage of Cetuximab-IRDye800CW at 1 day, Number of (S)AEs and SUSARs and 1 more. Status: unknown.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05929456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929456.